167 related articles for article (PubMed ID: 37721470)
1. The Cyclooxygenase 2 Inhibitor Etoricoxib as Adjunctive Therapy in Tuberculosis Impairs Macrophage Control of Mycobacterial Growth.
Nore KG; Louet C; Bugge M; Gidon A; Jørgensen MJ; Jenum S; Dyrhol-Riise AM; Tonby K; Flo TH
J Infect Dis; 2024 Mar; 229(3):888-897. PubMed ID: 37721470
[TBL] [Abstract][Full Text] [Related]
2. Monocytic myeloid-derived suppressor cells reflect tuberculosis severity and are influenced by cyclooxygenase-2 inhibitors.
Jøntvedt Jørgensen M; Jenum S; Tonby K; Mortensen R; Walzl G; Du Plessis N; Dyrhol-Riise AM
J Leukoc Biol; 2021 Jul; 110(1):177-186. PubMed ID: 33155730
[TBL] [Abstract][Full Text] [Related]
3. Plasma LOX-Products and Monocyte Signaling Is Reduced by Adjunctive Cyclooxygenase-2 Inhibitor in a Phase I Clinical Trial of Tuberculosis Patients.
Jøntvedt Jørgensen M; Nore KG; Aass HCD; Layre E; Nigou J; Mortensen R; Tasken K; Kvale D; Jenum S; Tonby K; Dyrhol-Riise AM
Front Cell Infect Microbiol; 2021; 11():669623. PubMed ID: 34307194
[TBL] [Abstract][Full Text] [Related]
4. A Phase I/II randomized trial of H56:IC31 vaccination and adjunctive cyclooxygenase-2-inhibitor treatment in tuberculosis patients.
Jenum S; Tonby K; Rueegg CS; Rühwald M; Kristiansen MP; Bang P; Olsen IC; Sellæg K; Røstad K; Mustafa T; Taskén K; Kvale D; Mortensen R; Dyrhol-Riise AM
Nat Commun; 2021 Nov; 12(1):6774. PubMed ID: 34811370
[TBL] [Abstract][Full Text] [Related]
5. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
6. TREM2 Promotes Immune Evasion by Mycobacterium tuberculosis in Human Macrophages.
Dabla A; Liang YC; Rajabalee N; Irwin C; Moonen CGJ; Willis JV; Berton S; Sun J
mBio; 2022 Aug; 13(4):e0145622. PubMed ID: 35924849
[TBL] [Abstract][Full Text] [Related]
7. The Effects of Oral Liposomal Glutathione and In Vitro Everolimus in Altering the Immune Responses against
To K; Cao R; Yegiazaryan A; Owens J; Sasaninia K; Vaughn C; Singh M; Truong E; Sathananthan A; Venketaraman V
Biomol Concepts; 2021 May; 12(1):16-26. PubMed ID: 33966361
[TBL] [Abstract][Full Text] [Related]
8. The Tumor Necrosis Factor Alpha and Interleukin 6 Auto-paracrine Signaling Loop Controls Mycobacterium avium Infection via Induction of IRF1/IRG1 in Human Primary Macrophages.
Gidon A; Louet C; Røst LM; Bruheim P; Flo TH
mBio; 2021 Oct; 12(5):e0212121. PubMed ID: 34607464
[TBL] [Abstract][Full Text] [Related]
9. [Frontier of mycobacterium research--host vs. mycobacterium].
Okada M; Shirakawa T
Kekkaku; 2005 Sep; 80(9):613-29. PubMed ID: 16245793
[TBL] [Abstract][Full Text] [Related]
10. [Prospects for development of new antituberculous drugs].
Tomioka H
Kekkaku; 2002 Aug; 77(8):573-84. PubMed ID: 12235850
[TBL] [Abstract][Full Text] [Related]
11. The COX- inhibitor indomethacin reduces Th1 effector and T regulatory cells in vitro in Mycobacterium tuberculosis infection.
Tonby K; Wergeland I; Lieske NV; Kvale D; Tasken K; Dyrhol-Riise AM
BMC Infect Dis; 2016 Oct; 16(1):599. PubMed ID: 27776487
[TBL] [Abstract][Full Text] [Related]
12. Lactic acid bacteria enhance autophagic ability of mononuclear phagocytes by increasing Th1 autophagy-promoting cytokine (IFN-gamma) and nitric oxide (NO) levels and reducing Th2 autophagy-restraining cytokines (IL-4 and IL-13) in response to Mycobacterium tuberculosis antigen.
Ghadimi D; de Vrese M; Heller KJ; Schrezenmeir J
Int Immunopharmacol; 2010 Jun; 10(6):694-706. PubMed ID: 20381647
[TBL] [Abstract][Full Text] [Related]
13. MiR-1178 regulates mycobacterial survival and inflammatory responses in Mycobacterium tuberculosis-infected macrophages partly via TLR4.
Shi G; Mao G; Xie K; Wu D; Wang W
J Cell Biochem; 2018 Sep; 119(9):7449-7457. PubMed ID: 29781535
[TBL] [Abstract][Full Text] [Related]
14. Modulating macrophage function to reinforce host innate resistance against
Park HE; Lee W; Choi S; Jung M; Shin MK; Shin SJ
Front Immunol; 2022; 13():931876. PubMed ID: 36505429
[No Abstract] [Full Text] [Related]
15. Priming of innate antimycobacterial immunity by heat-killed
Luukinen H; Hammarén MM; Vanha-Aho LM; Svorjova A; Kantanen L; Järvinen S; Luukinen BV; Dufour E; Rämet M; Hytönen VP; Parikka M
Dis Model Mech; 2018 Jan; 11(1):. PubMed ID: 29208761
[TBL] [Abstract][Full Text] [Related]
16. Innate cytokine profiling of bovine alveolar macrophages reveals commonalities and divergence in the response to Mycobacterium bovis and Mycobacterium tuberculosis infection.
Magee DA; Conlon KM; Nalpas NC; Browne JA; Pirson C; Healy C; McLoughlin KE; Chen J; Vordermeier HM; Gormley E; MacHugh DE; Gordon SV
Tuberculosis (Edinb); 2014 Jul; 94(4):441-50. PubMed ID: 24882682
[TBL] [Abstract][Full Text] [Related]
17. The immunosuppressive effects of a novel recombinant LipQ (Rv2485c) protein of Mycobacterium tuberculosis on human macrophage cell lines.
Kumar A; Manisha ; Sangha GK; Shrivastava A; Kaur J
Microb Pathog; 2017 Jun; 107():361-367. PubMed ID: 28412202
[TBL] [Abstract][Full Text] [Related]
18. N-acetyl-cysteine exhibits potent anti-mycobacterial activity in addition to its known anti-oxidative functions.
Amaral EP; Conceição EL; Costa DL; Rocha MS; Marinho JM; Cordeiro-Santos M; D'Império-Lima MR; Barbosa T; Sher A; Andrade BB
BMC Microbiol; 2016 Oct; 16(1):251. PubMed ID: 27793104
[TBL] [Abstract][Full Text] [Related]
19. Host-directed anti-mycobacterial activity of colchicine, an anti-gout drug, via strengthened host innate resistance reinforced by the IL-1β/PGE
Kwon KW; Kim LH; Kang SM; Lee JM; Choi E; Park J; Hong JJ; Shin SJ
Br J Pharmacol; 2022 Aug; 179(15):3951-3969. PubMed ID: 35301712
[TBL] [Abstract][Full Text] [Related]
20. The timing of TNF and IFN-gamma signaling affects macrophage activation strategies during Mycobacterium tuberculosis infection.
Ray JC; Wang J; Chan J; Kirschner DE
J Theor Biol; 2008 May; 252(1):24-38. PubMed ID: 18321531
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
